|
|
The wait is over.
Boey® is now available in Canada.
|
|
|
|
From the makers of BOTOX COSMETIC®, Boey® is the first and
only rapid-onset, short-duration neurotoxin for the temporary
improvement of moderate to severe frown lines.1
|
|
Boey® offers a new
option for patients who
may be curious about
aesthetic treatment
but are not yet ready
to commit to longer-
lasting results.
|
|
|
Boey® is now available to order.
|
| |
|
Visit Allergan Direct or contact your Allergan Aesthetics
representative to order Boey® today.
|
|
|
|
Want to learn more about Boey®?
|
| |
|
Secure Your Spot
Join us on October 7 for
Unlock a New Era of Neurotoxin: Introducing Boey®
|
|
|
| |
|
|
|
|
You received this email because you signed up to receive communications from Allergan Aesthetics, and AbbVie Corporation division (“AbbVie”). If you no longer wish to receive communications from Allergan Aesthetics, you may withdraw your consent at any time by emailing MKH-Customer-OptOut@allergan.com.
This product may not be available to all healthcare providers. Availability depends on your province and scope of practice, and purchase requires confirmation of applicable authorization.
Allergan Aesthetics, an AbbVie company,
1380 Rodick Rd. Suite 300, Markham, ON L3R 4G5
© 2026 AbbVie. All rights reserved.
† Boey® is the first botulinum neurotoxin approved in aesthetics based on botulinum neurotoxin type E.
It has a distinct pharmacologic profile, with onset of effect observed within hours after injection and a duration of response that lasted approximately 2–3 weeks. Due to its early onset of effect and short duration, Boey® should be used occasionally. No other aesthetic neurotoxin with this clinical profile has previously been approved.1,2
1. BOEY® Product Monograph. Date of Authorization: June 30, 2026.
2. Lain et al., Rapid Results With TrenibotulinumtoxinE for the Treatment of Glabellar Lines
in Toxin-Naive Adults: Safety, Efficacy, and Satisfaction Findings From a Pivotal Phase 3
Study, Aesthetic Surgery Journal, 2026.
CA-TRENI-260028
|
